1STBIO develops novel therapeutics targeting neurodegenerative diseases, immuno-oncology, and rare diseases through a genomic-based target discovery platform. The company addresses significant unmet medical needs by transforming breakthrough scientific discoveries into effective medicines for patients.

BIORCHESTRA develops RNA-based therapeutics specifically designed to target and modify gene expression in neurodegenerative diseases. This approach aims to provide precise treatment options that address the underlying genetic factors contributing to conditions such as Alzheimer's and Parkinson's disease.

C-Biomex develops theranostics using its proprietary peptide discovery platform, CUS™, which identifies stable and selective peptides through a high-purity library, novel screening procedures, and direct sequencing. This technology addresses the need for precise diagnostic and therapeutic solutions in the radiopharmaceuticals market.

Curocell utilizes genetically modified immune cells to enhance anti-tumor responses in patients with cancer, specifically targeting immune suppression within tumor microenvironments. This technology aims to improve treatment efficacy across various cancer types, providing new therapeutic options for patients facing limited alternatives.

Dareesoft offers a Road Hazard Information as a Service (RiaaS) platform that utilizes on-device AI to automatically detect and transmit real-time data on over 12 types of road hazards, including potholes. This service enhances road safety by providing municipalities with actionable insights and high-quality hazard images, enabling efficient maintenance and reducing accident risks.

The startup develops therapeutic vaccines using E. coli-based virus-like particle (VLP) technology to produce recombinant proteins aimed at treating infectious diseases such as norovirus and hand, foot, and mouth disease (HFMD). By leveraging this protein biotechnology, the company enhances the ability of medical professionals to combat these viral infections effectively.

iN Therapeutics is a biotechnology platform specializing in drug development targeting ion channels to create therapies for patients with incurable neurological diseases, including chronic pain and amyotrophic lateral sclerosis. The company utilizes a proprietary ion channel compound library and electrophysiological research techniques to address the unmet medical needs of these conditions.

KaiPharm utilizes proprietary virtual drug-screening technology and drug-induced transcriptome data to accelerate the identification of potential drug candidates. This approach addresses the lengthy and costly process of traditional drug discovery by enhancing the efficiency of lead compound selection.

MBD specializes in 3D cell culture platforms, providing advanced tools for precision medicine and drug development. Their Cellvitro® technology enables more accurate testing of drug efficacy and sensitivity, addressing the limitations of traditional 2D cell cultures in biomedical research.

Nearthlab provides an AI-powered automated industrial inspection solution that utilizes autonomous drones equipped with smart analytics to deliver precise data across various sectors, including public safety and wind power. This technology addresses the need for efficient and accurate inspections, reducing operational risks and enhancing safety protocols in complex environments.

The startup develops antidepressants and cognitive enhancers that improve brain plasticity and reduce neuroinflammation, targeting conditions such as dementia, depression, and Alzheimer's. By monitoring mental health and enhancing synaptic function, the company aims to prevent cognitive degradation in patients.

Organoid Sciences specializes in organoid-based drug discovery and regenerative medicine, utilizing 3D cultured stem cells to create miniaturized organs that closely mimic human tissue. The company addresses the challenge of organ shortages and the need for personalized treatment options for incurable diseases through its advanced drug screening and regenerative therapeutic platforms.

The startup specializes in upcycling automotive batteries through disassembly, repair, and reassembly processes to restore their original performance and extend their lifecycle. This approach reduces battery replacement costs and enables the reuse of batteries for various applications, including uninterruptible power supplies and mobility solutions.

Travel Wallet offers a digital travel wallet application that enables users to load and manage multiple currencies on a single card, eliminating foreign exchange fees and allowing for instant refunds of unused balances. The platform supports transactions in 46 currencies and provides contactless payment options, streamlining the payment process for travelers while reducing costs associated with traditional credit card usage.

Wdgbook is a mobile‑first wedding planning platform that consolidates venue discovery, AI‑driven hall recommendations, and a free digital invitation designer into a single app. Couples can browse and filter wedding halls, receive personalized suggestions, manage tasks and timelines, and create lifelong digital invitations, all accessed via QR‑code onboarding.

Tionlab Therapeutics develops long-acting injection systems for drug delivery, specifically targeting patients with diabetes and cancer. By enabling monthly injections, the company provides a more convenient method for medication administration, improving patient adherence and quality of life.